Brilliant Violet 421™ anti-mouse CD140a

Antibodies Single
Sony
APA5
Flow Cytometry
Rat IgG2a, κ
Mouse
Mouse PDGFR-α-hIgG1 recombinant fusion protein
50 µg
1279615
$272.00

Description

Platelet-derived growth factor receptor-α (PDGFR-α), CD140a, is one of two receptors for platelet-derived growth factors (PDGFs) and binds to all isoforms of PDGFs: PDGF-AA, PDGF-AB, and PDGF-BB. PDGFRa is a receptor tyrosine kinase that forms homodimers or heterodimers on the surface upon ligand binding and phosphorylates substrates. PDGFRs consist of either homodimers of α/α, β/β, or heterodimers of α/β. PDGF receptors, α and β, are single glycoproteins with intracellular tyrosine kinase domain. Their ligand, PDGF, is a mitogen for connective tissue and glial cells. CD140a is expressed on embryonic tissues and mesenchymal-derived cells of adult mice. PDGF plays a role in wound healing and acts as a chemoattractant for fibroblasts, smooth muscle cells, glial cells, monocytes, and neutrophils.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

  1. Takakura N, et al. 1996. J. Invest. Dermatol. 107:770.
  2. Liao C, et al. 2010. J. Clin. Invest. 120:242. (Block)
  3. Chen H, et al. 2015. ASN Neuro 8:7. PubMed